Al­to Neu­ro­science bags $25M for four Phase II drugs

An­oth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech at­tempt­ing to fix the “tri­al and er­ror” sys­tem in neu­ro­science drug R&D.

Al­to Neu­ro­science …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER